SG11201701853YA - Pyrrolopyrimidine derivatives as nr2b nmda receptor antagonists - Google Patents
Pyrrolopyrimidine derivatives as nr2b nmda receptor antagonistsInfo
- Publication number
- SG11201701853YA SG11201701853YA SG11201701853YA SG11201701853YA SG11201701853YA SG 11201701853Y A SG11201701853Y A SG 11201701853YA SG 11201701853Y A SG11201701853Y A SG 11201701853YA SG 11201701853Y A SG11201701853Y A SG 11201701853YA SG 11201701853Y A SG11201701853Y A SG 11201701853YA
- Authority
- SG
- Singapore
- Prior art keywords
- receptor antagonists
- nmda receptor
- pyrrolopyrimidine derivatives
- nr2b nmda
- nr2b
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462050692P | 2014-09-15 | 2014-09-15 | |
| PCT/US2015/050267 WO2016044323A1 (fr) | 2014-09-15 | 2015-09-15 | Dérivés de pyrrolopyrimidine à titre d'antagonistes des récepteurs nmda nr2b |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201701853YA true SG11201701853YA (en) | 2017-04-27 |
Family
ID=54293326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201701853YA SG11201701853YA (en) | 2014-09-15 | 2015-09-15 | Pyrrolopyrimidine derivatives as nr2b nmda receptor antagonists |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US9567341B2 (fr) |
| EP (1) | EP3194403B1 (fr) |
| JP (1) | JP6612331B2 (fr) |
| KR (1) | KR102569031B1 (fr) |
| CN (1) | CN106715435B (fr) |
| AU (1) | AU2015317886A1 (fr) |
| CA (1) | CA2957898C (fr) |
| DK (1) | DK3194403T3 (fr) |
| ES (1) | ES2723436T3 (fr) |
| IL (1) | IL251027A0 (fr) |
| MX (1) | MX2017002775A (fr) |
| RU (1) | RU2017107558A (fr) |
| SG (1) | SG11201701853YA (fr) |
| WO (1) | WO2016044323A1 (fr) |
| ZA (1) | ZA201701069B (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015271719A1 (en) * | 2014-06-04 | 2016-12-01 | Rugen Holdings (Cayman) Limited | Difluoroethylpyridine derivatives as NR2B NMDA receptor antagonists |
| JP6612331B2 (ja) | 2014-09-15 | 2019-11-27 | リューゲン ホールディングス （ケイマン） リミテッド | Ｎｒ２ｂ ｎｍｄａ受容体アンタゴニストとしてのピロロピリミジン誘導体 |
| WO2016126869A1 (fr) | 2015-02-04 | 2016-08-11 | Rugen Holdings (Cayman) Limited | Dérivés 3,3-difluoro-pipéridine en tant qu'antagonistes des récepteurs nmda nr2b |
| ES2784398T3 (es) | 2015-06-01 | 2020-09-24 | Rugen Holdings Cayman Ltd | Compuestos heterocíclicos de 3,3-difluoropiperidina carbamato como antagonistas del receptor de NMDA NR2B |
| US10487055B2 (en) | 2016-06-01 | 2019-11-26 | Rhode Island Board Of Education | Diindole compounds useful in treatment of nervous system disorders |
| WO2018098128A1 (fr) | 2016-11-22 | 2018-05-31 | Rugen Holdings (Cayman) Limited | Traitement de troubles du spectre autistique, de troubles obsessivo-compulsifs et de troubles de l'anxiété |
| AU2018379438B2 (en) * | 2017-12-08 | 2022-08-18 | Boehringer Ingelheim International Gmbh | Imidazopyridine derivatives and the use thereof as medicament |
| EP4074317A1 (fr) | 2021-04-14 | 2022-10-19 | Bayer AG | Dérivés de phosphore en tant que nouveaux inhibiteurs de sos1 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9610766A (pt) | 1995-08-11 | 1999-07-13 | Pfizer | Triihdrato de metanossulfonato de (1s,2s)-1-(4-hidróxi-fenil)-2-(4-hidróxi-4-fenilpiperidin-1-il)-1-propanol |
| US6476041B1 (en) | 1999-10-29 | 2002-11-05 | Merck & Co., Inc. | 1,4 substituted piperidinyl NMDA/NR2B antagonists |
| HU227197B1 (en) | 2000-10-24 | 2010-10-28 | Richter Gedeon Nyrt | Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them |
| HUP0303258A3 (en) * | 2001-02-23 | 2004-06-28 | Merck & Co Inc | N-substituted nonaryl-heterocyclic nmda/nr2b antagonists and pharmaceutical compositions containing them |
| DK1648882T3 (da) | 2003-06-04 | 2008-11-24 | Merck & Co Inc | 3-fluor-piperidiner som NMDA/NR2B-antagonister |
| US7592360B2 (en) | 2003-06-04 | 2009-09-22 | Merck & Co., Inc. | 3-fluoro-piperidines as NMDA/NR2B antagonists |
| ES2279446T3 (es) * | 2003-08-15 | 2007-08-16 | MERCK & CO., INC. | Antagonistas nmda/nr2b de 4-cicloalquilaminopirazolo pirimidina. |
| WO2005102390A2 (fr) | 2004-04-22 | 2005-11-03 | Pfizer Japan, Inc. | Combinaisons comprenant des ligands alpha-2-delta et des antagonistes des recepteurs de nmda |
| US20070293515A1 (en) | 2004-08-03 | 2007-12-20 | Layton Mark E | 1,3-Disubstituted Heteroaryl Nmda/Nr2b Antagonists |
| JP2008525486A (ja) | 2004-12-22 | 2008-07-17 | メルク エンド カムパニー インコーポレーテッド | 置換ピペリジンの製造方法 |
| JP2008536927A (ja) * | 2005-04-19 | 2008-09-11 | メルク エンド カムパニー インコーポレーテッド | Ｎ−アルキル−アザシクロアルキルｎｍｄａ／ｎｒ２ｂ拮抗物質 |
| PT1913000E (pt) * | 2005-07-29 | 2012-02-28 | Pfizer Prod Inc | Derivados de pirrolo[2,3-d]pirimidina, suas substâncias intermédias e processo de síntese |
| WO2007061868A2 (fr) | 2005-11-17 | 2007-05-31 | Trustees Of Tufts College | Traitement de comportements stereotypiques compulsifs et predisposant a l'automutilation, utilisant des inhibiteurs specifiques du recaptage de la serotonine (ssri) et des antagonistes des recepteurs nmda |
| EP2520567A3 (fr) | 2006-02-23 | 2012-12-12 | Shionogi & Co., Ltd. | Dérivés d'hétérocycle contenant de l'azote substitués avec un groupe cyclique |
| AU2007338408B2 (en) | 2006-12-27 | 2012-07-26 | Sanofi-Aventis | Substituted isoquinoline and isoquinolinone derivatives |
| WO2010015637A1 (fr) | 2008-08-06 | 2010-02-11 | Novartis Ag | Nouveaux nucléosides modifiés antiviraux |
| US20130096115A1 (en) | 2009-12-28 | 2013-04-18 | Afraxis, Inc. | Methods for treating autism |
| DK2558446T5 (da) | 2010-04-16 | 2019-12-09 | Ac Immune Sa | Nye forbindelser til behandling af sygdomme associerede med amyloid- eller amyloidlignende proteiner |
| EP2580213A4 (fr) | 2010-06-09 | 2013-12-25 | Afraxis Holdings Inc | 8-(hétéroarylméthyl)pyrido[2,3-d]pyrimidin-7(8h)-ones pour le traitement de troubles du snc |
| WO2011159945A2 (fr) | 2010-06-16 | 2011-12-22 | Afraxis, Inc. | Procédés pour traiter des affections neurologiques |
| US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| US20140005188A1 (en) | 2011-03-11 | 2014-01-02 | Glaxo Group Limited | Pyrido[3,4-b]pyrazine derivatives as syk inhibitors |
| ES2634716T3 (es) | 2011-05-31 | 2017-09-28 | Celgene International Ii Sàrl | Nuevos estabilizantes y moduladores del receptor GLP-1 |
| JP6042968B2 (ja) | 2012-04-20 | 2016-12-14 | ユセベ ファルマ ソシエテ アノニム | パーキンソン病の処置方法 |
| BR112015018094A2 (pt) | 2013-01-29 | 2017-07-18 | Naurex Inc | moduladores de receptor nmda de espiro-lactama e usos dos mesmos |
| US20170072005A1 (en) | 2014-05-06 | 2017-03-16 | Northwestern University | Combinations of nmdar modulating compounds |
| AU2015271719A1 (en) | 2014-06-04 | 2016-12-01 | Rugen Holdings (Cayman) Limited | Difluoroethylpyridine derivatives as NR2B NMDA receptor antagonists |
| JP6612331B2 (ja) | 2014-09-15 | 2019-11-27 | リューゲン ホールディングス （ケイマン） リミテッド | Ｎｒ２ｂ ｎｍｄａ受容体アンタゴニストとしてのピロロピリミジン誘導体 |
| WO2016049048A1 (fr) | 2014-09-22 | 2016-03-31 | Rugen Holdings (Cayman) Limited | Traitement des troubles de l'anxiété et des troubles du spectre autistique |
| WO2016100349A2 (fr) | 2014-12-16 | 2016-06-23 | Rugen Holdings (Cayman) Limited | Composés azahétérocycliques bicycliques utilisés comme antagonistes des récepteurs nmda nr2b |
| WO2016126869A1 (fr) | 2015-02-04 | 2016-08-11 | Rugen Holdings (Cayman) Limited | Dérivés 3,3-difluoro-pipéridine en tant qu'antagonistes des récepteurs nmda nr2b |
| ES2784398T3 (es) | 2015-06-01 | 2020-09-24 | Rugen Holdings Cayman Ltd | Compuestos heterocíclicos de 3,3-difluoropiperidina carbamato como antagonistas del receptor de NMDA NR2B |
| WO2018098128A1 (fr) | 2016-11-22 | 2018-05-31 | Rugen Holdings (Cayman) Limited | Traitement de troubles du spectre autistique, de troubles obsessivo-compulsifs et de troubles de l'anxiété |
-
2015
- 2015-09-15 JP JP2017514306A patent/JP6612331B2/ja active Active
- 2015-09-15 CN CN201580049617.5A patent/CN106715435B/zh active Active
- 2015-09-15 KR KR1020177010056A patent/KR102569031B1/ko active IP Right Grant
- 2015-09-15 MX MX2017002775A patent/MX2017002775A/es unknown
- 2015-09-15 AU AU2015317886A patent/AU2015317886A1/en not_active Abandoned
- 2015-09-15 EP EP15779059.3A patent/EP3194403B1/fr active Active
- 2015-09-15 CA CA2957898A patent/CA2957898C/fr active Active
- 2015-09-15 DK DK15779059.3T patent/DK3194403T3/en active
- 2015-09-15 WO PCT/US2015/050267 patent/WO2016044323A1/fr active Application Filing
- 2015-09-15 ES ES15779059T patent/ES2723436T3/es active Active
- 2015-09-15 SG SG11201701853YA patent/SG11201701853YA/en unknown
- 2015-09-15 US US14/855,010 patent/US9567341B2/en active Active
- 2015-09-15 RU RU2017107558A patent/RU2017107558A/ru not_active Application Discontinuation
-
2017
- 2017-02-09 US US15/428,321 patent/US9968610B2/en active Active
- 2017-02-13 ZA ZA2017/01069A patent/ZA201701069B/en unknown
- 2017-03-08 IL IL251027A patent/IL251027A0/en unknown
-
2018
- 2018-04-24 US US15/961,553 patent/US10420768B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20180303834A1 (en) | 2018-10-25 |
| KR102569031B1 (ko) | 2023-08-22 |
| US9567341B2 (en) | 2017-02-14 |
| US20160075713A1 (en) | 2016-03-17 |
| IL251027A0 (en) | 2017-04-30 |
| JP2017526724A (ja) | 2017-09-14 |
| JP6612331B2 (ja) | 2019-11-27 |
| EP3194403A1 (fr) | 2017-07-26 |
| RU2017107558A (ru) | 2018-10-18 |
| US20170209449A1 (en) | 2017-07-27 |
| CA2957898A1 (fr) | 2016-03-24 |
| ES2723436T3 (es) | 2019-08-27 |
| CN106715435B (zh) | 2019-10-01 |
| AU2015317886A1 (en) | 2017-03-09 |
| MX2017002775A (es) | 2017-08-10 |
| US10420768B2 (en) | 2019-09-24 |
| BR112017004868A2 (pt) | 2017-12-12 |
| RU2017107558A3 (fr) | 2019-03-18 |
| CN106715435A (zh) | 2017-05-24 |
| WO2016044323A1 (fr) | 2016-03-24 |
| DK3194403T3 (en) | 2019-04-15 |
| EP3194403B1 (fr) | 2019-02-06 |
| KR20170049602A (ko) | 2017-05-10 |
| CA2957898C (fr) | 2023-02-21 |
| ZA201701069B (en) | 2019-07-31 |
| US9968610B2 (en) | 2018-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1252163A1 (zh) | 受體 | |
| GB201514875D0 (en) | Receptor | |
| IL251027A0 (en) | History of pyrrolopyrimidines as nr2b nmda receptor antagonists | |
| EP3137074A4 (fr) | Antagonistes du récepteur ep2 des prostaglandines, dérivés, compositions et utilisations associés | |
| HK1243638A1 (zh) | 甲氨蝶呤製劑 | |
| HRP20182016T1 (hr) | Derivati etinila | |
| HRP20181585T1 (hr) | Selektivni nr2b antagonisti | |
| EP3154956A4 (fr) | Antagonistes du glucagon | |
| EP3136858A4 (fr) | Guanosine comme potentialisatrice du système immunitaire à médiation par les récepteurs toll | |
| EP3350167A4 (fr) | Antagonistes du récepteur des androgènes | |
| HK1247916A1 (zh) | 新型5-ht2拮抗劑 | |
| EP3865472C0 (fr) | Antagonistes du récepteur de thromboxane | |
| EP3193852A4 (fr) | Antagonistes du récepteur nmda pour traiter la maladie de gaucher | |
| HK1231414A1 (zh) | 胃輕癱用 受體激動劑 | |
| TWM489280U (en) | Vibrator table structure |